Structured evidence table for Prebiotic Gut Health Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Prebiotic Gut Health Meta-Analysis | Reduced SCFA production is consistently observed in metabolic and inflammatory disorders [], whereas interventions that increase SCFAs improve metabolic outcomes in both animal and human studies []. | 1 | Alshatari Sumaya (2026) | Effects of Polyphenol Supplementation on Gut Microbiota Composition and Fecal Short-Chain Fatty Acids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Prebiotic Gut Health Meta-Analysis | Epidemiological studies link higher polyphenol intake to reduced risk of chronic diseases [], traditionally attributed to antioxidant and anti-inflammatory properties []. | 1 | Alshatari Sumaya (2026) | Effects of Polyphenol Supplementation on Gut Microbiota Composition and Fecal Short-Chain Fatty Acids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Prebiotic Gut Health Meta-Analysis | Current mechanistic evidence is largely predicated on in vitro and animal models, with a notable scarcity of synthesized data from human randomized controlled trials (RCTs) [,]. | 1 | Alshatari Sumaya (2026) | Effects of Polyphenol Supplementation on Gut Microbiota Composition and Fecal Short-Chain Fatty Acids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Prebiotic Gut Health Meta-Analysis | 1 2 3 4 The human gastrointestinal tract harbors a dense, diverse microbial ecosystem of approximately 10microorganisms, collectively known as the gut microbiota []. | 1 | Alshatari Sumaya (2026) | Effects of Polyphenol Supplementation on Gut Microbiota Composition and Fecal Short-Chain Fatty Acids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Prebiotic Gut Health Meta-Analysis | 1 2 3 4 5 5 Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has emerged as the most common chronic liver disorder worldwide and a critical component of the global metabolic disease pandemic (,). | 4 | Zhao Yinan (2026) | Impact of probiotics and prebiotics on glucose/lipid metabolism in metabolic dysfunction-associated steatotic liver disease: mechanisms and implications |
| Prebiotic Gut Health Meta-Analysis | Recent epidemiological evidence indicates that MASLD currently affects approximately 38% of the global adult population, with prevalence steadily increasing over the past decades as obesity and metabolic disorders become more widespread (). | 4 | Zhao Yinan (2026) | Impact of probiotics and prebiotics on glucose/lipid metabolism in metabolic dysfunction-associated steatotic liver disease: mechanisms and implications |
| Prebiotic Gut Health Meta-Analysis | Individuals with metabolic risk factors, notably those with type 2 diabetes, demonstrate particularly elevated prevalence rates, with over 65% of diabetic individuals affected, and face an increased risk of progression to more severe disease phenotypes (–). | 4 | Zhao Yinan (2026) | Impact of probiotics and prebiotics on glucose/lipid metabolism in metabolic dysfunction-associated steatotic liver disease: mechanisms and implications |
| Prebiotic Gut Health Meta-Analysis | MASLD is defined by the presence of hepatic steatosis in conjunction with metabolic dysfunction, including obesity, insulin resistance, dyslipidemia, or type 2 diabetes (,). | 4 | Zhao Yinan (2026) | Impact of probiotics and prebiotics on glucose/lipid metabolism in metabolic dysfunction-associated steatotic liver disease: mechanisms and implications |
Source documents